Amyloid PET findings in multiple sclerosis are associated with cognitive decline at 18 months.

Cognitive impairment Florbetaben Multiple sclerosis Myelin Positron emission tomography

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
02 Jan 2020
Historique:
received: 13 11 2019
revised: 16 12 2019
accepted: 01 01 2020
pubmed: 10 1 2020
medline: 10 1 2020
entrez: 10 1 2020
Statut: aheadofprint

Résumé

To study the clinical, cognitive, and radiological progression of a cohort of patients with MS, taking into account the amyloid PET with Twenty-nine patients with MS were assessed with longitudinal structural MRI and a clinical and comprehensive neuropsychological protocol, with a mean interval between assessments of 18 ± 3.31 months. Patients with cognitive decline over the follow-up period showed a lower standardised uptake value ratio in NAWM and lower thalamic volume and a higher lesion load in the baseline MRI. Myelin status was correlated with EDSS and cognitive tests mainly evaluating visuospatial function and working memory. Lower uptake in NAWM at baseline was also associated with a growth in white matter lesion volume over time. Lower white matter uptake in amyloid PET is associated with cognitive decline and an increase in white matter lesion volume during the follow-up. Our study suggests that

Identifiants

pubmed: 31918239
pii: S2211-0348(20)30002-X
doi: 10.1016/j.msard.2020.101926
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101926

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Vanesa Pytel (V)

Department of Neurology, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

Jordi A Matias-Guiu (JA)

Department of Neurology, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain. Electronic address: jordi.matias-guiu@salud.madrid.org.

Jorge Matías-Guiu (J)

Department of Neurology, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

Ana Cortés-Martínez (A)

Department of Neurology, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

Paloma Montero (P)

Department of Neurology, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

Teresa Moreno-Ramos (T)

Department of Neurology, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

Juan Arrazola (J)

Department of Radiology, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

José Luis Carreras (JL)

Department of Nuclear Medicine, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

María Nieves Cabrera-Martín (MN)

Department of Nuclear Medicine, Hospital Clínico San Carlos. San Carlos Health Research Institute (IdISSC) Complutense University of Madrid. Calle Prof. Martín Lagos s/n. 28040. Madrid, Spain.

Classifications MeSH